Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.65 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.54 |
| ▸ | FRK | P42685 | 1/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.54 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.54 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.54 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.54 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.54 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.54 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.54 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.54 |
| ▸ | NR1I3 | Q14994 | 6/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7851176 | 0.87 | PTGS2 (0.76) | PTGS2PTGS1ERBB4PRKD3MAP4K4 | |
| SCHEMBL1691880 | 0.80 | NR1I3 (0.56) | PTGS2PTGS1NR1I3IDO1HSD17B10 | |
| SCHEMBL22648873 | 0.79 | DYRK1A (0.56) | PTGS2PTGS1NR1I3IDO1HSD17B10 | |
| SCHEMBL14209732 | 0.79 | PTGS2 (0.61) | PTGS2PTGS1ERBB4PRKD3MAP4K4 | |
| SCHEMBL14209812 | 0.78 | PTGS2 (0.64) | PTGS2PTGS1ERBB4PRKD3MAP4K4 | |
| SCHEMBL14209710 | 0.78 | PTGS2 (0.60) | PTGS2PTGS1ERBB4PRKD3MAP4K4 | |
| SCHEMBL1429234 | 0.78 | PTGS2 (0.64) | PTGS2PTGS1ERBB4PRKD3MAP4K4 | |
| SCHEMBL3246464 | 0.77 | PTGS2 (1.00) | PTGS2PTGS1ERBB4PRKD3MAP4K4 | |
| SCHEMBL3240378 | 0.77 | PTGS2 (1.00) | PTGS2PTGS1ERBB4PRKD3MAP4K4 | |
| SCHEMBL18203558 | 0.77 | AKT1 (0.56) | NR1I3NR1I2AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9387204-B2 | Fused bicyclic imidazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-07-12 | — | — | US | disclosed |
| US-20140088110-A1 | FUSED BICYCLIC IMIDAZOLES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-27 | — | — | US | disclosed |
| US-8592591-B2 | Fused bicyclic imidazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-26 | — | — | US | disclosed |
| EP-2176259-B1 | FUSED IMIDAZOLES FOR CANCER TREATMENT | BAYER SCHERING PHARMA AG (DE) | 2011-03-30 | — | — | EP | disclosed |
| EP-2176259-A1 | FUSED IMIDAZOLES FOR CANCER TREATMENT | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-04-21 | — | — | EP | disclosed |
| US-20090156604-A1 | FUSED BICYCLIC IMIDAZOLES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| EP-2062893-A1 | Fused imidazoles for cancer treatment | Bayer Schering Pharma AG (DE) | 2009-05-27 | — | — | EP | disclosed |
| WO-2009021990-A1 | FUSED IMIDAZOLES FOR CANCER TREATMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088110-A1 | FUSED BICYCLIC IMIDAZOLES | MTOR, AKT2, AKT1 | PTGS2 2828/4885PTGS1 2383/4885ERBB4 169/4885 |
| US-20090156604-A1 | FUSED BICYCLIC IMIDAZOLES | MTOR, AKT2, AKT1 | PTGS2 2828/4885PTGS1 2383/4885ERBB4 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.